177Lu-DOTA-Octreotate
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 177Lu-DOTA-Octreotate, covering 2023-03-20 to 2025-02-20. Get the full timeline:
Most recent: Clinical Trial Update: PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours [Phase 1]